Nothing new for science in Fed budget
15 May, 2002 by Daniella GoldbergPouring millions into defence and border security, with cuts in health and welfare, this year's Federal budget carries no significant investment for science and technology.
Milestone payments for Peptech's D2E7
14 May, 2002 by Daniella GoldbergPeptech has received its first milestone payment from its agreement with Abbott Laboratories to market the rheumatoid arthritis drug D2E7.
Biotech festival begins with call for science teachers
14 May, 2002 by Tanya HollisVictoria's week-long festival of biotechnology education kicked off last night (May 13) with a call for more specially trained teachers.
Analysing venture capital
13 May, 2002 by Daniella GoldbergVenture capitalists need to be as a good at analysing their clients as any psychiatrist, says Dr Mike Hirshorn, a medical doctor turned venture capitalist, now with Sydney-based VC Nanyang Ventures.
The Mitchell viewpoint
13 May, 2002 by Melissa TrudingerDr Graham Mitchell is in a unique position to comment on biotechnology in Victoria. As one of the four scientists in biotech consultancy Foursight Associates, he is one of the chief scientific advisers to the Victorian government.
How to achieve perfect pitch
13 May, 2002 by Daniella GoldbergWith years of experience in the business of science and training as a scientist as well as in business management, Cerylid Biosciences CEO Dr Jackie Fairley is well equipped to give advice on the pitch, whether it's in the elevator or at a venture capital forum.
Biotech 'grossly under-invested': QIC
13 May, 2002 by Melissa TrudingerAustralia's biotechnology sector is "grossly under-invested" and attracts little interest from most funds and investors, according to a senior portfolio manager at Queensland Investment Corporation.
Industry heavyweight calls for better R&D base
13 May, 2002 by Iain ScottEffective R&D policy would include more flexible career opportunities for scientists, according to Vision Systems managing director Dr Jim Fox.
Qld's biotech bid grows by another $100m
10 May, 2002 by Melissa TrudingerThe Queensland government has gone one-up on the State and Federal governments by announcing a new $100 million Queensland BioCapital Fund.
Aeris to market indoor biofilm technology
10 May, 2002 by Iain Scott'Environmental biotechnology' usually conveys a mental image of vats of bacteria busily working on soil remediation. But the issue of indoor air quality is fast becoming an important area of focus in the life sciences arena, according to Sydney-based company Aeris Technologies.
Axon announces loss, shares drop
10 May, 2002 by Tanya HollisShares in Axon Instruments suffered a kick in the guts after a shareholder update revealed unexpected losses of up to $US4 million in the six months to June.
VCs to run new $107m pre-seed plan
10 May, 2002 by Pete YoungLarge venture capital entities have snared all four of the licences to manage the Federal government's new $107 million plan to fill the pre-seed funding gap facing promising technologies.
CSL slide continues despite 'buy' status
10 May, 2002 by Tanya HollisInvestors continued to punish biotech big gun CSL today, despite analysts recommending the stock as a definite buy.
HIPAA compliance: the clock is ticking
09 May, 2002 by Cara GarretsonWith the first deadline to implement new medical record regulations less than a year away, bioscience companies should be taking a hard look at whether these complicated US federal mandates will affect them.
MBAs told to go offshore for biotech experience
08 May, 2002 by Daniella GoldbergBusiness management students were told yesterday that they may have to work overseas before they sought employment in Australia's biotechnology industry.
